作者
Alice Boilève,Jérôme Cartry,Negaar Goudarzi,Sabrina Bedja,Jacques R.R. Mathieu,Mohamed Amine Bani,Rémy Nicolle,Ali Mouawia,Ryme Bouyakoub,Claudio Nicotra,Maud Ngo‐Camus,Bastien Job,Karélia Lipson,V. Boige,Marine Valéry,Anthony Tarabay,Peggy Dartigues,Lambros Tselikas,Thierry de Baère,Antoîne Italiano,Simona Cosconea,Maximiliano Gelli,Elena Fernandez-De-Sevilla,Maxime Annereau,David Malka,Cristina Smolenschi,Michel Ducreux,Antoine Hollebecque,Fanny Jaulin
摘要
Patient-derived organoids (PDOs) are promising tumor avatars that could enable ex vivo drug tests to personalize patients' treatments in the frame of functional precision oncology. However, clinical evidence remains scarce. This study aims to evaluate whether PDOs can be implemented in clinical practice to benefit patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC).
藤椒辣鱼
毛豆
cocolu
Cochrane
Yifan2024
ceeray23
jyy
sutharsons
嗯哼
SYLH
敬老院1号
小宋
小红薯7XJ9B2Q4
嘻哈hang
无限面包
从容的无极
haosu
genomed
七月流火
Phoenix
皖公网安备34019202002308
